#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15204	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2458	753.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1630	1630	C	927	C,G	926,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15204	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2458	753.1	0	HET	.	.	.	C260T,G,A	.	260	260	C	706	706	C	864	C,T,G,A	674,188,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25802	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4213	762.8	0	.	n	.	0	T695C	SNP	695	695	T	1457	1457	C	887	C,T,G	883,2,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25802	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4213	762.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	2099	2099	A	1076	A,C	1070,6	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25802	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4213	762.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2733	2733	C	953	C,T,A	950,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25802	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4213	762.8	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3359	3359	T	842	T,A,G	839,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25802	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4213	762.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2807	2807	A	906	A	906	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2344	folP	852	852	100.0	folP.l15.c4.ctg.1	2141	136.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1363	1365	AGC	211;213;213	A;G;C,G	211;213;212,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5292	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	4009	164.3	1	SNP	p	S91F	0	.	.	271	273	TCC	897	899	TCC	190;190;189	T,C,A;C;C	188,1,1;190;189	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5292	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	4009	164.3	1	SNP	p	D95G	0	.	.	283	285	GAC	909	911	GAC	195;196;197	G;A;C	195;196;197	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5292	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	4009	164.3	1	SNP	p	D95N	0	.	.	283	285	GAC	909	911	GAC	195;196;197	G;A;C	195;196;197	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	1944	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1919	126.2	1	SNP	p	G45D	1	.	.	133	135	GAC	822	824	GAC	208;210;212	G;A;C	208;210;211	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1112	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	1524	90.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4992	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3434	180.9	1	SNP	p	D86N	0	.	.	256	258	GAC	881	883	GAC	237;240;241	G;A;C	237;240;241	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4992	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3434	180.9	1	SNP	p	S87I	0	.	.	259	261	AGT	884	886	AGT	242;244;239	A,C;G,C;T	241,1;243,1;239	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4992	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3434	180.9	1	SNP	p	S87W	0	.	.	259	261	AGT	884	886	AGT	242;244;239	A,C;G,C;T	241,1;243,1;239	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4992	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3434	180.9	1	SNP	p	S87R	0	.	.	259	261	AGT	884	886	AGT	242;244;239	A,C;G,C;T	241,1;243,1;239	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4992	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3434	180.9	1	SNP	p	S88P	0	.	.	262	264	TCC	887	889	TCC	242;239;242	T,G;C;C	241,1;239;242	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4372	parE	1986	1986	100.0	parE.l6.c30.ctg.1	3254	167.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1852	1854	GGC	242;244;238	G,T;G,A;C	241,1;243,1;238	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3892	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3118	155.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1598	1600	GCA	241;240;236	G,T;C;A,T,G	240,1;240;234,1,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3892	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3118	155.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1601	1603	ATC	236;238;239	A,C;T,G;C,T	235,1;237,1;238,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3892	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3118	155.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1613	1615	GTG	249;251;251	G,C;T,C;G	248,1;250,1;251	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3892	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3118	155.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1613	1615	GTG	249;251;251	G,C;T,C;G	248,1;250,1;251	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3892	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3118	155.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2117	2119	ACC	195;195;194	A,G;C,G;C,G	194,1;194,1;193,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3892	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3118	155.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2171	2173	GCG	191;191;193	G;C;G,C	190;190;191,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3892	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3118	155.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2171	2173	GCG	191;191;193	G;C;G,C	190;190;191,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3892	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3118	155.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2294	2296	GGC	199;199;200	G;G,A;C,A	199;198,1;199,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3892	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3118	155.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2303	2305	GGC	201;201;200	G;G;C	201;201;200	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3892	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3118	155.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2321	2323	CCG	201;205;207	C;C,G;G	201;204,1;207	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5596	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3622	192.5	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1862	1864	CTG	227;226;225	C,G;T;G	226,1;226;225	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2666	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2345	141.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	874	874	C	199	C	199	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	G38E	NONSYN	112	114	GGA	782	784	GAA	248;253;254	G;A;A,T	248;253;253,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	S46G	NONSYN	136	138	AGC	806	808	GGC	244;248;248	G,A;G,A;C,A	243,1;247,1;246,2	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	E48G	NONSYN	142	144	GAA	812	814	GGA	243;246;250	G;G,A;A	243;245,1;250	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	T87A	NONSYN	259	261	ACT	929	931	GCT	229;228;228	G,T;C;T,A	228,1;228;227,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	T89S	NONSYN	265	267	ACC	935	937	AGC	220;222;224	A;G;C,T	220;222;223,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	.	MULTIPLE	358	359	AA	1027	1028	CG	210;212	C,A;G,C,A	209,1;210,1,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	.	MULTIPLE	361	362	GA	1030	1032	CAG	213;215;213	C,A;A,C;G,T	212,1;214,1;212,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	N122K	NONSYN	364	366	AAC	1034	1036	AAA	208;215;214	A;A,C;A,C	208;214,1;213,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	K143E	NONSYN	427	429	AAA	1097	1099	GAA	237;239;236	G,A;A;A,C	236,1;238;234,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	V151A	NONSYN	451	453	GTA	1121	1123	GCA	248;248;246	G;C;A	248;248;246	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1313	1315	ACT	231;228;230	A;C;T	231;228;230	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1322	1324	ATG	226;228;230	A;T;G,A,T	226;228;228,1,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1436	1438	GCA	198;200;201	G;C;A	198;200;201	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1439	1441	ACG	201;200;200	A;C;G	201;200;200	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	S258G	NONSYN	772	774	AGT	1442	1444	GGG	203;203;202	G,C;G,T;G,T	202,1;202,1;201,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1445	1447	GTT	201;202;200	G;T,A;T	201;201,1;200	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1505	1507	GTA	214;220;221	G;T;A	214;220;221	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1544	1546	ACT	215;217;216	A;C;T	215;216;216	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1550	1552	GAT	221;222;221	G;A;T,G	221;222;220,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1562	1564	CAC	229;229;228	C;A,C;C	229;228,1;228	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	1	SNP	p	G120K	1	.	.	358	360	AAG	1027	1029	CGG	210;212;211	C,A;G,C,A;G	209,1;210,1,1;211	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	1	SNP	p	D121N	0	.	.	361	363	GAC	1030	1033	CGC	213;213;214	C,A;G,T;C,T	212,1;212,1;213,1	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2736	porB1b	1047	1047	97.04	porB1b.l6.c4.ctg.1	1870	180.0	1	SNP	p	A121D	1	.	.	361	363	GAC	1030	1033	CGC	213;213;214	C,A;G,T;C,T	212,1;212,1;213,1	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9572	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5367	222.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2265	2267	AAT	218;217;218	A;A;T	218;217;218	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1390	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1582	109.4	1	SNP	p	V57M	1	.	.	169	171	ATG	755	757	ATG	214;212;211	A,T;T;G	213,1;212;211	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
